Please ensure Javascript is enabled for purposes of website accessibility

Merrimack Pharmaceuticals Inc Dropped 18.2% in April Despite Positive Developments

By Brian Feroldi - May 8, 2016 at 6:21AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares tanked even though the company had a handful of positive developments occur during the month.

What: Investors in Merrimack Pharmaceuticals (MACK 4.75%) , a biopharmaceutical company primarily focused on cancer, had a rough April. The company's stock lost more than 18% of its value during the period, according to data from S&P Global Market Intelligence.

MACK Chart

So what: The company didn't release any negative news during the month, so I'm left scratching my head as to why shares fell so hard.

In fact, Merrimack announced two positive news items during the period:

  • Merrimack announced a strategic partnership with Leica Biosystems, a German company that specializes in creating cancer diagnostic equipment. The two companies will work together to develop a diagnostic assay that will make it easier to identify patients who have cancers that could be treated with one of Merrimack's compounds.
  • The company introduced a new compound to healthcare providers and investors that Merrimack is calling MM-310. Merrimack believes that this drug holds the potential to be an effective treatment for a wide range of cancers, including breast, lung, and prostate.

Now what: Regardless of these developments, investors continue to focus their attention on Onivyde, Merrimack's recently launched pancreatic cancer drug. The company sold $4.3 million worth of product in the fourth quarter, but that only included two months of sales. (Onivyde officially launched on October 26th.) 

The National Comprehensive Cancer Network recently added Onivyde to its list of clinical-practice guidelines for treating patients with pancreatic adenocarcinoma. This development should make it easier for the company to build awareness for the drug.

Merrimack has announced that it will be holding an analyst day on May 19 to give investors more information about its pipeline and commercialization plans for Onivyde. Anyone who is either bullish or bearish on this company's stock will want to tune in.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merrimack Pharmaceuticals, Inc. Stock Quote
Merrimack Pharmaceuticals, Inc.
MACK
$5.95 (4.75%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.